Cargando…
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?
Idiopathic pulmonary fibrosis (IPF) is a disease that carries a high mortality. Pulmonary hypertension (PH) frequently complicates the course of patients with IPF and is associated with significantly worse outcomes. Whether PH is a surrogate or driver of these worse outcomes remains unanswered, but...
Autores principales: | Nathan, Steven D, King, Christopher S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085308/ https://www.ncbi.nlm.nih.gov/pubmed/25061279 http://dx.doi.org/10.2147/DDDT.S64907 |
Ejemplares similares
-
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
por: Brereton, Christopher J., et al.
Publicado: (2020) -
Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2020) -
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2019) -
Updates in pulmonary hypertension and other pulmonary vascular diseases
por: Bernardo, Roberto J., et al.
Publicado: (2019) -
GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)